BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21922338)

  • 1. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
    Lam VW; Spiro C; Laurence JM; Johnston E; Hollands MJ; Pleass HC; Richardson AJ
    Ann Surg Oncol; 2012 Apr; 19(4):1292-301. PubMed ID: 21922338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases.
    Kawamura J; Yazawa T; Sumida K; Kida Y; Ogawa R; Tani M; Kawasoe J; Yamamoto M; Harada H; Yamamoto H; Zaima M
    World J Surg Oncol; 2016 Feb; 14():56. PubMed ID: 26911142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
    Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
    BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
    Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
    Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological management of unresectable liver metastases.
    Prenen H; Van Cutsem E
    Dig Dis; 2012; 30 Suppl 2():137-42. PubMed ID: 23207946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
    Adam R; Aloia T; Lévi F; Wicherts DA; de Haas RJ; Paule B; Bralet MP; Bouchahda M; Machover D; Ducreux M; Castagne V; Azoulay D; Castaing D
    J Clin Oncol; 2007 Oct; 25(29):4593-602. PubMed ID: 17925554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H
    Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
    Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
    Mima K; Beppu T; Chikamoto A; Miyamoto Y; Nakagawa S; Kuroki H; Okabe H; Hayashi H; Sakamoto Y; Watanabe M; Kikuchi K; Baba H
    Int J Clin Oncol; 2013 Oct; 18(5):847-55. PubMed ID: 22940848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
    Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neoadjuvant therapy concepts for liver metastases].
    Folprecht G; Bechstein WO
    Chirurg; 2011 Nov; 82(11):989-94. PubMed ID: 22033894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases.
    Devaud N; Kanji ZS; Dhani N; Grant RC; Shoushtari H; Serrano PE; Nanji S; Greig PD; McGilvray I; Moulton CA; Wei A; Gallinger S; Cleary SP
    HPB (Oxford); 2014 May; 16(5):475-80. PubMed ID: 23927606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
    Min BS; Kim NK; Ahn JB; Roh JK; Kim KS; Choi JS; Cha SH; Kim H
    Onkologie; 2007 Dec; 30(12):637-43. PubMed ID: 18063876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
    Power DG; Kemeny NE
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):251-64. PubMed ID: 20970353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
    Masi G; Cupini S; Marcucci L; Cerri E; Loupakis F; Allegrini G; Brunetti IM; Pfanner E; Viti M; Goletti O; Filipponi F; Falcone A
    Ann Surg Oncol; 2006 Jan; 13(1):58-65. PubMed ID: 16372158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases.
    Lam VW; Laurence JM; Johnston E; Hollands MJ; Pleass HC; Richardson AJ
    HPB (Oxford); 2013 Jul; 15(7):483-91. PubMed ID: 23750490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.